Literature DB >> 15186228

Linear IgA dermatosis with IgA and IgG autoantibodies to the 180 kDa bullous pemphigoid antigen (BP180): evidence for a distinct subtype.

Brandie J Metz1, Sun Young Ruggeri, Sylvia Hsu, Jon A Reed, Ali S Ghohestani, Jouni Uitto, Reza F Ghohestani.   

Abstract

BACKGROUND: Autoantibodies in linear immunoglobulin A (IgA) disease (LAD) are reported to be of IgA class and directed against a 97-120 kDa epidermal antigen.
METHODS: We report a 39-year-old woman with clinical features of LAD and with circulating IgA and IgG autoantibodies to the 180 kDa bullous pemphigoid antigen (BP180).
RESULTS: Histopathology of lesional skin revealed a subepidermal blister with mixed inflammatory cell infiltrate. Direct immunofluorescence of perilesional skin showed linear deposits of IgA along the dermal-epidermal junction. The antigen specificity of the patient's circulating antibodies was determined by Western blotting and enzyme-linked immunoabsorbent assay (ELISA) using various antigen sources, including cultured human keratinocytes, dermal protein lysates, and purified laminin-5, as well as proteins corresponding to BP180, the 230 kDa bullous pemphigoid antigen (BP230), laminin-5 subunits, and collagen IV alpha1-alpha6 chains. IgA and IgG antibodies in the patient's serum were directed against BP180, and no IgA or IgG reactivity was found against the other skin antigens.
CONCLUSIONS: These data provide evidence for the presence of a subtype of LAD with dual IgA and IgG autoimmune response to BP180.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15186228     DOI: 10.1111/j.1365-4632.2004.02016.x

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


  2 in total

1.  Immunologic overlap in a case of linear IgG/IgA bullous dermatosis responsive to rituximab.

Authors:  Dmitry Nedosekin; Kelsey Derrick Wilson; Katelynn Campbell; Sara Shalin; Henry K Wong
Journal:  JAAD Case Rep       Date:  2021-01-11

Review 2.  Humoral Epitope Spreading in Autoimmune Bullous Diseases.

Authors:  Dario Didona; Giovanni Di Zenzo
Journal:  Front Immunol       Date:  2018-04-17       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.